Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Research & Development (2020 - 2025)

Historic Research & Development for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $19.8 million.

  • GeneDx Holdings' Research & Development rose 6998.71% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 2736.19%. This contributed to the annual value of $45.7 million for FY2024, which is 2152.89% down from last year.
  • According to the latest figures from Q3 2025, GeneDx Holdings' Research & Development is $19.8 million, which was up 6998.71% from $15.1 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Research & Development high stood at $53.1 million for Q1 2021, and its period low was $10.9 million during Q2 2024.
  • For the 5-year period, GeneDx Holdings' Research & Development averaged around $18.0 million, with its median value being $14.6 million (2023).
  • Data for GeneDx Holdings' Research & Development shows a peak YoY increase of 12730.92% (in 2022) and a maximum YoY decrease of 5988.37% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows GeneDx Holdings' Research & Development stood at $22.2 million in 2021, then increased by 9.53% to $24.4 million in 2022, then plummeted by 49.73% to $12.2 million in 2023, then fell by 5.39% to $11.6 million in 2024, then surged by 71.12% to $19.8 million in 2025.
  • Its last three reported values are $19.8 million in Q3 2025, $15.1 million for Q2 2025, and $12.6 million during Q1 2025.